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Abstract
BACKGROUND: Infectious disease epidemiology has changed over time, reflecting improved 
clinical interventions and emergence of threats such as antimicrobial resistance. This study 
investigated infectious disease hospitalizations in the United States from 2001 to 2014.
METHODS: Estimated rates of infectious disease hospitalizations were calculated by using the 
National (Nationwide) Inpatient Sample. Infectious disease hospitalizations were defined as 
hospitalizations with a principal discharge diagnosis of an infectious disease. Diagnoses according 
to site of infection and sepsis were examined, as was occurrence of in-hospital death. The leading 
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nonsepsis infectious disease secondary diagnoses for hospitalizations with a principal diagnosis of 
sepsis were identified.
RESULTS: The mean annual age-adjusted infectious disease hospitalization rate was 1,468.2 
(95% CI, 1,459.9-1,476.4) per 100,000 population; in-hospital death occurred in 4.22% (95% CI, 
4.18-4.25) of infectious disease hospitalizations. The mean annual age-adjusted infectious disease 
hospitalization rate increased from 2001-2003 to 2012-2014 (rate ratio, 1.05; 95% CI, 1.01-1.09), 
as did the percentage of in-hospital death (4.21% [95% CI, 4.13-4.29] to 4.30% [95% CI, 
4.26-4.35]; P = .049). The diagnoses with the highest hospitalization rates among all sites of 
infection and sepsis diagnoses were the lower respiratory tract followed by sepsis. The most 
common nonsepsis infectious disease secondary diagnoses among sepsis hospitalizations were 
“urinary tract infection,” “pneumonia, organism unspecified,” and “intestinal infection due to 
Clostridium [Clostridioides] difficile.”
CONCLUSIONS: Although hospital discharge data are subject to limitations, particularly for 
tracking sepsis, lower respiratory tract infections and sepsis seem to be important contributors to 
infectious disease hospitalizations. Prevention of infections that lead to sepsis and improvements 
in sepsis management would decrease the burden of infectious disease hospitalizations and 
improve outcomes, respectively.
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Infectious diseases cause widespread morbidity and mortality worldwide every year.1 In the 
past century, there have been improvements in sanitation, vaccination, and health care that 
have driven declines in infectious disease incidence and mortality.1,2 Nevertheless, there are 
ongoing challenges in infectious disease control. Although clinical interventions continue to 
improve, sepsis remains a major cause of morbidity and mortality.3 Antimicrobial resistance 
is an increasingly recognized concern.4 Meanwhile, naturally occurring emerging infectious 
disease events are on the rise.5
Analyzing the burden and trends in infectious disease hospitalizations across the United 
States is one means of evaluating the impact of infectious diseases. Studies since 1980 have 
reported both increases and decreases in infectious disease hospitalizations depending on the 
organ system affected, the pathogen, and the subpopulation.6-11 An updated analysis is 
needed of infectious disease hospitalizations for more recent years in the United States. In 
addition, earlier studies did not evaluate infectious disease hospitalizations according to 
pathogen type and organ system as exclusive classifications. We therefore investigated the 
burden and trends in infectious disease hospitalizations in the United States from 2001 to 
2014.
Materials and Methods
Data Source
The National (Nationwide) Inpatient Sample (NIS) was used to analyze hospital discharge 
data with an infectious disease diagnosis for the general US population from 2001 to 2014.12 
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The NIS of the Healthcare Cost and Utilization Project (HCUP), sponsored by the Agency 
for Healthcare Cost and Utilization Project, is the largest all-payer, nationally representative 
inpatient database in the United States. For each discharge record in the NIS, we pulled up to 
15 diagnoses (principal diagnosis plus 14 secondary diagnoses) that were coded on the basis 
of the International Classification of Diseases, Ninth Revision, Clinical Modification 
(ICD-9-CM).13
Study Approval
Use of the NIS prohibits identification of individual patients. The current study was 
determined by the Centers for Disease Control and Prevention and the New York City 
Department of Health and Mental Hygiene not to be human subjects research.
Definitions
An infectious disease hospitalization was defined as a hospitalization with a principal 
diagnosis of an infectious disease. The principal diagnosis refers to “the condition 
established after study to be chiefly responsible for occasioning the admission of the patient 
to the hospital for care.”14 Infectious disease diagnoses were compiled through manual 
review of the ICD-9-CM code index, using ICD-9-CM codes identified in an earlier study as 
a model.11,13 Infectious disease diagnoses were separated into exclusive categories first 
according to site of infection or sepsis and then according to pathogen type (e-Tables 1, 2). 
ICD-9-CM codes for sepsis were analyzed with diagnoses according to site of infection, and 
a sepsis hospitalization was defined as a hospitalization with a principal diagnosis of sepsis.
Data Analysis
Estimates with SEs of the number of hospitalizations were calculated from the NIS by using 
the HCUP weighting methodology.12,15,16 The unit of analysis was a hospitalization; NIS 
data do not have person identifiers, and therefore repeat hospitalizations of the same patient 
were included.
Annual and mean annual hospitalization rates with 95% CIs were expressed as the weighted 
number of hospitalizations per 100,000 persons of the corresponding population. 
Denominators were taken from the National Center for Health Statistics’ annual bridged 
race population estimates for the study period.17,18 Age-adjusted rates with 95% CIs were 
calculated by using the direct method, with the 2000 projected US population as the 
standard; crude rates were calculated for specific age groups and income quartiles.19 Poisson 
regression was used to calculate rate ratios with 95% CIs.20 P values < .05 were considered 
statistically significant.
Infectious disease hospitalization discharges were examined according to year, sex, age, 
race/ethnicity, region, income quartile based on ZIP code, occurrence of in-hospital death, 
site of infection or sepsis, and pathogen type. To examine trends, mean annual rates for 
2001-2003 and 2012-2014 were compared. Income quartiles according to ZIP code were 
consistent for the year 2003 and later, and therefore analysis according to income quartile 
was restricted to 2003 to 2014. Some discharge records had missing information on sex 
(0.3% [SE, 0.01]), age (0.1% [SE, < 0.01]), race/ethnicity (17.8% [SE, 0.37]), and income 
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quartile according to ZIP code (2.5% [SE, 0.07]); adjustments were not made for missing 
data.
The 10 leading nonsepsis infectious disease secondary diagnoses for sepsis hospitalizations 
were identified. The most commonly listed individual infectious disease diagnoses within 
the “other or not specified” category according to site of infection and pathogen type were 
identified.
All analyses were generated by using SAS version 9.4 (SAS Institute, Inc.). Weighted 
estimates with corresponding SEs, as well as percentages with 95% CIs, were calculated by 
using SUDAAN (RTI International).
Results
From 2001 to 2014, there were 64,070,733 (SE, 302,981) hospitalizations listing an 
infectious disease as a principal diagnosis, corresponding to a mean annual age-adjusted rate 
of 1,468.2 (95% CI, 1,459.9-1,476.4) (Table 1). The annual rate of infectious disease 
hospitalizations varied each year, and the mean annual age-adjusted rate increased from 
2001-2003 to 2012-2014 (rate ratio, 1.05; 95% CI, 1.01-1.09) (Fig 1A, Table 2). In-hospital 
death occurred in 4.22% (95% CI, 4.18-4.25) of infectious disease hospitalizations over the 
entire study period; the percentage of in-hospital death was 4.21% (95% CI, 4.13-4.29) from 
2001 to 2003 and 4.30% (95% CI, 4.26-4.35) from 2012 to 2014 (P = .049).
Leading Principal Diagnoses
The most commonly listed principal diagnoses among infectious disease hospitalizations 
were “pneumonia, organism unspecified,” “unspecified septicemia,” and “urinary tract 
infection” (Table 3). Nearly one in five “unspecified septicemia” hospitalizations resulted in 
inhospital death, and 42.9% (SE, 0.2) of all infectious disease in-hospital deaths listed 
unspecified septicemia as the principal diagnosis.
Hospitalizations According to Demographic Group
Mean annual rates of infectious disease hospitalizations varied according to age group, with 
those aged ≥ 85 years having the highest rates followed by those aged < 1 year (Table 1). 
The percentage of infectious disease hospitalizations with in-hospital death increased with 
increasing age group above < 1 year. Mean annual rates of infectious disease hospitalizations 
decreased from 2001-2003 to 2012-2014 for the group aged < 18 years, increased for those 
aged 18 to 84 years, and remained unchanged for those aged ≥ 85 years (Table 2). The 
largest mean annual rate increase was observed for the group aged 45 to 64 years, which also 
had the largest absolute increase in percentage of in-hospital death from 2001-2003 to 
2012-2014 among all age groups. The largest absolute decrease in percentage of inhospital 
deaths from 2001-2003 to 2012-2014 occurred among those aged ≥ 85 years.
There was no significant difference in mean annual age-adjusted rate of infectious disease 
hospitalization according to sex, although male subjects experienced a higher percentage of 
in-hospital death than female subjects (Table 1).
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Non-Hispanic black subjects had the highest mean annual age-adjusted rate of infectious 
disease hospitalization of all race/ethnicities, and non-Hispanic Asian/Pacific Islander 
subjects had the lowest (Table 1). Non-Hispanic Asian/Pacific Islander subjects experienced 
the highest percentage of in-hospital death, and Hispanic subjects experienced the lowest 
(Table 2).
The South region had the highest mean annual age-adjusted rate of infectious disease 
hospitalization, and the West had the lowest (Table 1). The percentage of in-hospital death 
was highest in the Northeast and lowest in the Midwest.
Site of Infection and Sepsis
The diagnosis that occurred at the highest mean annual age-adjusted rate among all site of 
infection and sepsis diagnoses was the lower respiratory tract (Fig 1B, Table 4). The 
diagnoses that occurred at the lowest mean annual age-adjusted rates among all sites of 
infection and sepsis diagnoses were hematologic, lymphatic, or immune systems and 
cardiovascular system.
The mean annual age-adjusted rate of sepsis hospitalizations was 240.6 (95% CI, 
238.8-242.4), the second highest of all sites of infection and sepsis diagnoses; sepsis also 
carried the highest percentage of in-hospital death of all sites of infection and sepsis 
diagnoses (Table 4). The mean annual age-adjusted rate of sepsis hospitalizations tripled 
from 2001-2003 to 2012-2014; during the 2012 to 2014 period, sepsis occurred at a higher 
mean annual age-adjusted rate compared with all other sites of infection and sepsis 
diagnoses (Table 5). Sepsis accounted for 59.1% (SE, 0.2) of all infectious disease in-
hospital deaths over the entire study period. The most common nonsepsis infectious disease 
secondary diagnoses among sepsis hospitalizations were “urinary tract infection,” 
“pneumonia, organism unspecified,” and “intestinal infection due to Clostridium 
[Clostridioides] difficile” (e-Table 3).
The 10 most commonly listed diagnoses within the other or not specified site of infection are 
presented in e-Table 4.
Pathogen Type
The pathogen types that occurred at the highest mean annual age-adjusted rates were other 
or not specified and bacteria (other than TB) (Fig 1C, Table 4). The pathogen types that 
occurred at the lowest mean annual age-adjusted rates were TB and parasite.
The percentage of in-hospital death was highest for infectious disease hospitalizations for 
HIV and lowest for virus (other than HIV). The most commonly listed diagnoses in the other 
or not specified pathogen type category were “pneumonia, organism unspecified” and 
“unspecified septicemia.” These diagnoses accounted for 35.2% (SE, 0.1) and 18.3% (SE, 
0.1), respectively, of the other or not specified category (e-Table 4).
The largest relative decrease in mean annual age-adjusted rate of hospitalization from 
2001-2003 to 2012-2014 occurred for HIV and TB (Table 5). The percentage of in-hospital 
death increased from 2001-2003 to 2012-2014 for infectious disease hospitalizations 
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attributed to virus (other than HIV) and other or not specified; decreases were observed for 
all other pathogen types, including HIV.
Discussion
The current study describes infectious disease hospitalizations in the United States from 
2001 to 2014 using a national sample of hospital discharge data. We conducted this updated 
analysis of infectious disease hospitalizations to expand beyond published data focused on 
specific subpopulations within the United States and to provide the most current data for 
years in which ICD-9-CM codes were still in use.6-10 This analysis provides a comparison of 
how rates and outcomes of infectious disease hospitalizations changed over a time period 
when new vaccine recommendations were adopted in the United States (eg, rotavirus 
vaccine and pneumococcal vaccine), new prevention guidelines became available for health-
care-associated infections, resistance to certain antimicrobials became more widespread, and 
therapy for HIV became widely available, among other factors.4,21-25 We found that the 
overall rate and percentage of in-hospital death among infectious disease hospitalizations 
increased slightly from the beginning to the end of the study period. Stratifying these data 
according to demographic group, site of infection and sepsis, and pathogen type uncovered 
notable findings.
Observations of infectious disease hospitalization rates and outcomes according to age group 
likely reflect a number of important factors. Infectious disease hospitalization rates were 
highest among persons aged ≥ 85 years, followed by persons aged < 1 year, compared with 
all other age groups; however, when examining the trend over time, the infectious disease 
hospitalization rate remained unchanged for persons aged ≥ 85 years but decreased by one-
third for persons aged < 1 year. It is possible that the decline in infectious disease 
hospitalizations among persons aged < 1 year reflects factors such as use of pneumococcal 
conjugate vaccine and rotavirus vaccine during the study period.21,22 We also found that 
those in the oldest age group (≥ 85 years) experienced a higher percentage of in-hospital 
death compared with younger age groups. Although it is reassuring that the greatest absolute 
decrease in percentage of in-hospital death occurred in this oldest age group compared with 
all other age groups, we would recommend further investigation into factors such as 
utilization of palliative care and postdischarge destination. The greatest relative increase in 
infectious disease hospitalization rates was among those aged 45 to 64 years, and this age 
group also experienced an increase in percentage of in-hospital death. This finding 
highlights an area of further investigation.
Rates of infectious disease hospitalizations varied according to region, with the lowest rate 
in the West and the highest in the South; however, the percentage of inhospital death was 
lowest in the Midwest and highest in the Northeast. These observations regarding in-hospital 
death might specifically reflect geographic differences in the epidemiology of pneumonia, 
given that pneumonia accounted for > 20% of infectious disease hospitalizations. Pneumonia 
is a leading cause of death nationally.26 However, reported death rates for pneumonia vary 
according to jurisdiction; for example, the pneumonia death rate in New York City is 
reportedly higher than in some other cities in the country and the United States as a whole.
26-30
 If the Northeast region truly has a higher pneumonia death rate, it might offer a partial 
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explanation for the higher percentage of in-hospital death among infectious disease 
hospitalizations in the Northeast. Further investigation into the epidemiology of pneumonia 
in the Northeast compared with elsewhere in the country would help to address these 
observations.
The data underscore the burden of sepsis in the United States. Although sepsis was more 
frequently listed than any particular site of infection other than the lower respiratory tract 
over the entire study period, it was more frequently listed than any particular site of infection 
from 2012 to 2014. Indeed, the rate of sepsis hospitalizations tripled from the beginning of 
the study period to the end. Despite these data, it would be incorrect to conclude based on 
this study that the rate of sepsis truly increased across the country over the study period. 
Rather, we know that for sepsis, hospital discharge data are a less objective estimate of 
sepsis burden than clinical data, particularly because hospital discharge data are subject to 
coding biases (eg, the prioritization of the listing of sepsis as the principal diagnosis over 
other infectious disease diagnoses such as pneumonia).3,31,32 In addition, awareness and 
recognition of sepsis might also have increased over the study period, further contributing to 
the increased rate of sepsis hospitalizations that we observed. 33 Nevertheless, these data 
underscore the fact that sepsis can carry a poor prognosis. Furthermore, the three most 
commonly listed nonsepsis secondary diagnoses listed on the discharge record (“urinary 
tract infection”; “pneumonia, organism unspecified”; and “intestinal infection due to 
Clostridium [Clostridioides] difficile”) are all infection types that can be associated with the 
health-care setting. Thus, interventions to reduce these three infection types, particularly 
within the health-care setting, might be particularly impactful in reducing infectious disease 
burden.
Our observations according to pathogen type were not surprising. The most common 
pathogen types that we observed were other or not specified and bacteria (other than TB). 
The high rate of other or not specified pathogen type is to be expected, given that even when 
rigorous diagnostic approaches are applied, an etiologic agent for an episode of pneumonia 
or sepsis (the two most common infectious disease diagnoses that contributed to this 
category) might not be identified.34,35 The reductions in rates of hospitalization and 
percentage of in-hospital death for HIV and TB from the beginning to the end of the study 
period are reassuring and likely reflect advances in treatment and prevention strategies for 
HIV during this time.25
Although discharge data are useful for understanding infectious disease morbidity and 
mortality, there are limitations. Estimates of infectious disease hospitalizations may be 
affected by inaccuracies within discharge data such that the positive predictive value, 
sensitivity, and specificity of ICD-9-CM codes for particular pathogens can be highly 
variable.36-39 Discharge data can be affected by external factors such as reimbursement 
policies, possibly altering the selection and distribution of principal and secondary 
diagnoses.40 The NIS data do not allow the identification of individuals, and therefore repeat 
visits were not analyzed. We created two novel mutually exclusive classification schemes for 
site of infection and sepsis and pathogen type, but the classifications of ICD-9-CM codes 
may have been imperfect.
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Conclusions
Despite the notable limitations of hospital discharge data, there is clear evidence that 
infectious diseases are an important source of morbidity and mortality nationally. Although 
progress has been made in areas such as HIV and TB control, pneumonia seems to be a large 
contributor to infectious disease hospitalizations. Interventions to prevent infections that lead 
to sepsis and which improve sepsis management would decrease the burden of infectious 
disease hospitalizations and improve outcomes, respectively.
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Figure 1. 
A-C, Annual age-adjusted rates of infectious disease hospitalizations, United States, 2001 to 
2014. A, Overall. B, According to site of infection. C, According to pathogen type.
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